Journal article
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Anna He, Bernd Merkel, James William L Brown, Lana Zhovits Ryerson, Ilya Kister, Charles B Malpas, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Tim Spelman, Guillermo Izquierdo, Sara Eichau, Maria Trojano, Alessandra Lugaresi, Raymond Hupperts, Patrizia Sola, Diana Ferraro, Jan Lycke, Francois Grand'Maison, Alexandre Prat Show all
LANCET NEUROLOGY | ELSEVIER SCIENCE INC | Published : 2020
Abstract
BACKGROUND: High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised that early commencement of high-efficacy therapy would be associated with reduced long-term disability. We therefore aimed to compare long-term disability outcomes between patients who started high-efficacy therapies within 2 years of disease onset with those who started 4-6 years after disease onset. METHODS: In this retrospective international observational study, we obtained data from the MSBase registry and the Swedish MS registry, which prospectively collect patient data that are specific to multiple sclerosis as part ..
View full abstractRelated Projects (2)
Grants
Funding Acknowledgements
National Health and Medical Research Council Australia and MS Society UK.